Year None20242023202220212020201920182017 May 14, 2024 Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 02, 2024 Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting Mar 18, 2024 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Mar 18, 2024 Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine Feb 27, 2024 Tenaya Therapeutics to Participate in Upcoming March Investor Conferences Feb 26, 2024 Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications Feb 08, 2024 Tenaya Therapeutics Announces Pricing of Underwritten Offering Jan 03, 2024 Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 18 of 18
May 14, 2024 Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 02, 2024 Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Mar 18, 2024 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar 18, 2024 Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
Feb 26, 2024 Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
